Tendie Bot

Tendie.bot

Login
CGC Articles
reddit/

CGC Surges 52% as Trump Plans Marijuana Reclassification

Canopy Growth (CGC) led a historic cannabis stock surge on December 13, 2025, after reports that the Trump administration plans to reclassify marijuana as a Schedule III drug. Reddit discussion on r/stocks highlighted the 52% jump and broader sector rally, with the Amplify Seymour Cannabis ETF gaining over 54%.

  1. Canopy Growth shares surged more than 52% on Friday after reports that the Trump administration plans to reclassify marijuana as a Schedule III drug.

  2. The broader cannabis sector rallied, with Tilray Brands gaining over 44% and the Amplify Seymour Cannabis ETF (CNBS) posting its best day on record with a 54% gain.

  3. Reddit discussion on r/stocks was highly bullish, with strong sentiment and high engagement as retail investors reacted to the policy shift.

What Happened

CGC
$CGC shares jumped more than 52% on Friday, December 13, 2025, following reports that the Trump administration plans to reclassify marijuana as a Schedule III drug. The Washington Post reported on Thursday that President Trump would direct federal agencies to ease restrictions on cannabis, reducing oversight to the same level as common prescription painkillers. The move triggered a massive rally across the cannabis sector, with
TLRY
$TLRY gaining over 44% and
IIPR
$IIPR surging nearly 9%.

The Amplify Seymour Cannabis ETF (CNBS) rallied more than 54%, marking its best day on record, as the entire sector benefited from the anticipated regulatory shift.

Reddit Reaction

Discussion on r/stocks was highly active, with a post about the cannabis rally receiving 612 upvotes and 156 comments. The post highlighted the scale of the move, noting that weed producers like

CGC
$CGC and Tilray led the surge. Sentiment across the subreddit was broadly bullish, with an average sentiment score of 0.57, as retail investors reacted to the news of potential federal reclassification.

CGC

Market Context

The reclassification to Schedule III would significantly reduce federal oversight of marijuana and its derivatives, aligning them with drugs like Tylenol with codeine and other common prescription medications. This represents a major shift from the current Schedule I classification, which imposes the strictest federal controls. The news drove a broad rally in cannabis stocks, with the sector seeing some of its largest single-day gains on record.

Subscribe to Tendie.bot for more market recaps.